Írsko - angličtina - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/5/25 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 20/5/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine; hydrochlorothiazide - film-coated tablet - 40/10/12.5 milligram(s) - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Spojené štáty - angličtina - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pre

Spojené štáty - angličtina - NLM (National Library of Medicine)

apotex corp. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure

Spojené štáty - angličtina - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets.                  control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national hi

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/5 - angiotensin ii antagonists and calcium channel blockers

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/10 - angiotensin ii antagonists and calcium channel blockers

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine-myl is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.